Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tiffany A. Kolniak"'
Autor:
Jack M. Sullivan, Edwin H. Yau, Tiffany A. Kolniak, Lowell G. Sheflin, R. Thomas Taggart, Heba E. Abdelmaksoud
Publikováno v:
Journal of Ophthalmology, Vol 2011 (2011)
Post-transcriptional gene silencing (PTGS) agents such as ribozymes, RNAi and antisense have substantial potential for gene therapy of human retinal degenerations. These technologies are used to knockdown a specific target RNA and its cognate protein
Externí odkaz:
https://doaj.org/article/6a9379a2309642b8b360e6c45163ad5c
Publikováno v:
Vision Research. 48(3):453-469
Development of post-transcriptional gene silencing (PTGS) agents for therapeutic purposes is an immense challenge in modern biology. Established technologies used to knockdown a specific target RNA and its cognate protein: antisense, ribozyme, RNAi,
Publikováno v:
Retinal Degenerative Diseases ISBN: 9781461406303
The development of efficacious and safe post transcriptional gene silencing (PTGS) agents is a challenging scientific endeavor that embraces “biocomplexity” at many levels. The target mRNA exhibits a level of structural complexity that profoundly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af50fb1bfb5bbdf6721843817db2e332
https://doi.org/10.1007/978-1-4614-0631-0_20
https://doi.org/10.1007/978-1-4614-0631-0_20
Autor:
Tiffany A. Kolniak, Jack M. Sullivan, Heba E. Abdelmaksoud, Edwin H. Yau, Lowell G. Sheflin, R. Thomas Taggart
Publikováno v:
Journal of Ophthalmology
Journal of Ophthalmology, Vol 2011 (2011)
Journal of Ophthalmology, Vol 2011 (2011)
Post-transcriptional gene silencing (PTGS) agents such as ribozymes, RNAi and antisense have substantial potential for gene therapy of human retinal degenerations. These technologies are used to knockdown a specific target RNA and its cognate protein
Publikováno v:
Chest. 128:242S
Publikováno v:
Chest. 128:239S